Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
-
BUSINESS Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
-
BUSINESS Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
-
BUSINESS Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
-
REGULATORY MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
-
BUSINESS “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
-
BUSINESS Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
-
BUSINESS Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
-
BUSINESS MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
-
REGULATORY Sales Tax Hike Expected to Hasten Separation of Dispensing from Medical Practice by Sapping Yakka-Saeki
October 19, 2012
-
REGULATORY PAFSC Committee Recommends Approval for Switch OTC Version of Epadel 2 Years after Frist Review
October 18, 2012
-
BUSINESS Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
-
BUSINESS MTPC’s Oral MS Treatment Charging towards Blockbuster Territory
October 16, 2012
-
BUSINESS Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
-
ACADEMIA We Would Like to Provide iPS Cells with Medical History Identification: Prof. Yamanaka of Kyoto University
October 15, 2012
-
BUSINESS Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
-
REGULATORY MHLW to Begin Pilot Study on Drug Risk Management Plans for Generics
October 12, 2012
-
ORGANIZATION Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
-
BUSINESS Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
-
BUSINESS Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…